To access this element change to forms mode OFF
Grant Award View - GA22075
Next Generation Targeting of DNA-Methylation in Poor Risk Lymphoid...
GA ID:
GA22075
Agency:
Department of Health and Aged Care
Approval Date:
10-Sep-2018
Publish Date:
19-Sep-2018
Category:
Medical Research
Grant Term:
1-Jan-2019 to 31-Dec-2022
Value (AUD):
$218,518.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 18/19 Health Output 1.1 Health policy Research and Analysis
Grant Program:
MRFF Next Generation Clinical Researchers Program Career Development Fellowship
Grant Activity:
Next Generation Targeting of DNA-Methylation in Poor Risk Lymphoid Cancer
Purpose:
|
Lymphoma and multiple myeloma (MM) are the most common blood cancers in Australia. Unfortunately, patients with T-cell lymphoma have much worse outcomes than those with B-cell lymphoma, and MM remains incurable. This fellowship seeks to develop better treatments for MM and T-cell lymphoma. Laboratory experiments will evaluate a new class of drug designed to inhibit a target called VPRBP in the myeloma cell. Associate Professor Shortt will also conduct a clinical trial of a drug called SGI-110 in T-cell lymphoma. |
Internal Reference ID:
MRF1160133
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
Monash University
Recipient ABN:
12 377 614 012
Grant Recipient Location
Suburb:
Clayton
Town/City:
Melbourne
Postcode:
3800
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
VIC
Postcode:
3800
Country:
AUSTRALIA